Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions	Sep. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 2,343.9	$ 1,224.6
Marketable securities	2,093.5	2,313.4
Accounts receivable, net	1,933.5	1,958.5
Due from anti-CD20 therapeutic programs	582.3	526.9
Inventory	751.8	929.9
Other current assets	743.2	687.6
Total current assets	8,448.2	7,640.9
Marketable securities	1,813.9	1,375.9
Property, plant and equipment, net	3,138.1	3,601.2
Operating lease assets	422.0	0.0
Intangible assets, net	3,392.4	3,120.0
Goodwill	5,746.1	5,706.4
Deferred tax asset	3,284.5	2,153.9
Investments and other assets	1,238.8	1,690.6
Total assets	27,484.0	25,288.9
Current liabilities:
Current portion of notes payable	1,495.3	0.0
Taxes payable	125.6	63.5
Accounts payable	382.2	370.5
Accrued expenses and other	2,429.1	2,861.2
Total current liabilities	4,432.2	3,295.2
Notes payable	4,458.2	5,936.5
Deferred tax liability	2,820.4	1,636.2
Long-term operating lease liabilities	410.5	0.0
Other long-term liabilities	1,370.9	1,389.4
Total liabilities	13,492.2	12,257.3
Commitments and contingencies
Biogen Idec Inc. shareholders' equity
Preferred stock, par value $0.001 per share	0.0	0.0
Common stock, par value $0.0005 per share	0.1	0.1
Additional paid-in capital	0.0	0.0
Accumulated other comprehensive loss	(92.3)	(240.4)
Retained earnings	17,065.2	16,257.0
Treasury stock, at cost	(2,977.1)	(2,977.1)
Total Biogen Inc. shareholders’ equity	13,995.9	13,039.6
Noncontrolling interests	(4.1)	(8.0)
Total equity	13,991.8	13,031.6
Total liabilities and equity	$ 27,484.0	$ 25,288.9